BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 36362070)

  • 21. PAX3-FOXO1 fusion gene in rhabdomyosarcoma.
    Linardic CM
    Cancer Lett; 2008 Oct; 270(1):10-8. PubMed ID: 18457914
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cancer-Specific Energy Metabolism in Rhabdomyosarcoma Cells Is Regulated by MicroRNA.
    Sugito N; Taniguchi K; Kuranaga Y; Ohishi M; Soga T; Ito Y; Miyachi M; Kikuchi K; Hosoi H; Akao Y
    Nucleic Acid Ther; 2017 Dec; 27(6):365-377. PubMed ID: 28981396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alveolar rhabdomyosarcoma-associated PAX3-FOXO1 promotes tumorigenesis via Hippo pathway suppression.
    Crose LE; Galindo KA; Kephart JG; Chen C; Fitamant J; Bardeesy N; Bentley RC; Galindo RL; Chi JT; Linardic CM
    J Clin Invest; 2014 Jan; 124(1):285-96. PubMed ID: 24334454
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Survival outcomes of patients with localized FOXO1 fusion-positive rhabdomyosarcoma treated on recent clinical trials: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
    Heske CM; Chi YY; Venkatramani R; Li M; Arnold MA; Dasgupta R; Hiniker SM; Hawkins DS; Mascarenhas L
    Cancer; 2021 Mar; 127(6):946-956. PubMed ID: 33216382
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of fusion gene status versus histology on risk-stratification for rhabdomyosarcoma: Retrospective analyses of patients on UK trials.
    Selfe J; Olmos D; Al-Saadi R; Thway K; Chisholm J; Kelsey A; Shipley J
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
    Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
    Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Negative correlation of single-cell
    Regina C; Hamed E; Andrieux G; Angenendt S; Schneider M; Ku M; Follo M; Wachtel M; Ke E; Kikuchi K; Henssen AG; Schäfer BW; Boerries M; Wagers AJ; Keller C; Hettmer S
    Life Sci Alliance; 2021 Sep; 4(9):. PubMed ID: 34187933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrent t(2;2) and t(2;8) translocations in rhabdomyosarcoma without the canonical PAX-FOXO1 fuse PAX3 to members of the nuclear receptor transcriptional coactivator family.
    Sumegi J; Streblow R; Frayer RW; Dal Cin P; Rosenberg A; Meloni-Ehrig A; Bridge JA
    Genes Chromosomes Cancer; 2010 Mar; 49(3):224-36. PubMed ID: 19953635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A rapid one-generation genetic screen in a Drosophila model to capture rhabdomyosarcoma effectors and therapeutic targets.
    Galindo KA; Endicott TR; Avirneni-Vadlamudi U; Galindo RL
    G3 (Bethesda); 2014 Dec; 5(2):205-17. PubMed ID: 25491943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Polycomb group (PcG) protein EZH2 supports the survival of PAX3-FOXO1 alveolar rhabdomyosarcoma by repressing FBXO32 (Atrogin1/MAFbx).
    Ciarapica R; De Salvo M; Carcarino E; Bracaglia G; Adesso L; Leoncini PP; Dall'Agnese A; Walters ZS; Verginelli F; De Sio L; Boldrini R; Inserra A; Bisogno G; Rosolen A; Alaggio R; Ferrari A; Collini P; Locatelli M; Stifani S; Screpanti I; Rutella S; Yu Q; Marquez VE; Shipley J; Valente S; Mai A; Miele L; Puri PL; Locatelli F; Palacios D; Rota R
    Oncogene; 2014 Aug; 33(32):4173-84. PubMed ID: 24213577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clonality and evolutionary history of rhabdomyosarcoma.
    Chen L; Shern JF; Wei JS; Yohe ME; Song YK; Hurd L; Liao H; Catchpoole D; Skapek SX; Barr FG; Hawkins DS; Khan J
    PLoS Genet; 2015 Mar; 11(3):e1005075. PubMed ID: 25768946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. FAK Signaling in Rhabdomyosarcoma.
    Perrone C; Pomella S; Cassandri M; Braghini MR; Pezzella M; Locatelli F; Rota R
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33182556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rhabdomyosarcoma: current challenges and their implications for developing therapies.
    Hettmer S; Li Z; Billin AN; Barr FG; Cornelison DD; Ehrlich AR; Guttridge DC; Hayes-Jordan A; Helman LJ; Houghton PJ; Khan J; Langenau DM; Linardic CM; Pal R; Partridge TA; Pavlath GK; Rota R; Schäfer BW; Shipley J; Stillman B; Wexler LH; Wagers AJ; Keller C
    Cold Spring Harb Perspect Med; 2014 Nov; 4(11):a025650. PubMed ID: 25368019
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The botanical drug PBI-05204, a supercritical CO
    Vaccaro S; Rossetti A; Porrazzo A; Camero S; Cassandri M; Pomella S; Tomaciello M; Macioce G; Pedini F; Barillari G; Marchese C; Rota R; Cenci G; Tombolini M; Newman RA; Yang P; Codenotti S; Fanzani A; Megiorni F; Festuccia C; Minniti G; Gravina GL; Vulcano F; Milazzo L; Marampon F
    Front Pharmacol; 2022; 13():1071176. PubMed ID: 36532747
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Expression of fusion gene PAX3/PAX7-FKHR and chromosomal aberration in rhabdomyosarcoma].
    Gao H; Ou YL; Zhang KR; Zhang ZB; Wang WL
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):42-7. PubMed ID: 17285543
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High Frequency of Tumor Propagating Cells in Fusion-Positive Rhabdomyosarcoma.
    Generali M; Satheesha S; Bode PK; Wanner D; Schäfer BW; Casanova EA
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Detection of PAX3-FKHR and PAX7-FKHR fusion transcripts in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction using paraffin-embedded tissue.
    Chen BF; Chen ML; Liang DC; Huang YW; Liu HC; Chen SH
    Zhonghua Yi Xue Za Zhi (Taipei); 1999 Feb; 62(2):86-91. PubMed ID: 10063718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Radioresistance in rhabdomyosarcomas: Much more than a question of dose.
    Camero S; Cassandri M; Pomella S; Milazzo L; Vulcano F; Porrazzo A; Barillari G; Marchese C; Codenotti S; Tomaciello M; Rota R; Fanzani A; Megiorni F; Marampon F
    Front Oncol; 2022; 12():1016894. PubMed ID: 36248991
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma.
    Böhm M; Wachtel M; Marques JG; Streiff N; Laubscher D; Nanni P; Mamchaoui K; Santoro R; Schäfer BW
    J Clin Invest; 2016 Nov; 126(11):4237-4249. PubMed ID: 27760049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. OLIG2 is a novel immunohistochemical marker associated with the presence of PAX3/7-FOXO1 translocation in rhabdomyosarcomas.
    Kaleta M; Wakulińska A; Karkucińska-Więckowska A; Dembowska-Bagińska B; Grajkowska W; Pronicki M; Łastowska M
    Diagn Pathol; 2019 Sep; 14(1):103. PubMed ID: 31493794
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.